Loading

logo

Journal of Breast Cancer Research

ISSN: 2769-2418

Mini Review Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/breastcancer.2.014

Sentinel lymph node biopsy in early breast cancer: A brief review

Sachin S Kadam1,*, Tejaswini Kadam2
  • 1Department of Surgical Oncology, Currae Cancer & Multispeciality Hospital, Mumbai, India
  • 2Department of Ophthalmology , Conwest & Jain Superspeciality Eye Hospital, Mumbai, India
+ Affiliations - Affiliations

Corresponding Author

Sachin S Kadam, kool_sachin555@outlook.com

Received Date: October 29, 2022

Accepted Date: November 11, 2022

Citation:

Kadam SS, Kadam T. Sentinel lymph node biopsy in early breast cancer: A brief review. J Breast Cancer Res. 2022;2(1):23-27. 


Copyright: © 2022 Kadam SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

In breast cancer, the status of the axillary lymph node decides the prognosis of the disease. Axillary lymph node dissection (ALND) was the traditional method to address the lymph node. Final histopathological examination is the confirmatory method to detect metastasis in axillary lymph node. As the tumor stage advances, the rate of metastasis in axillary lymph nodes increases, simultaneously. The positivity rate of axillary lymph nodes in early breast cancer is low as compared to locally advanced breast cancer. The role of Sentinel Lymph Node Biopsy (SLNB) has been emerged, established in early breast cancer and it is universally accepted by most of the medical centers, worldwide. SLNB is indicated in early breast cancer when there are clinically negative nodes by palpation and ultrasound examination. It is the procedure to stage the axilla and it has minimum morbidity as compared to ALND. ALND has been replaced by SLNB at many centers, worldwide. We have reviewed the potential SLNB research studies and prepared a brief review article.

Keywords

Sentinel lymph node, Early breast cancer, Axillary lymph node, Metastasis, Prognosis, Biopsy, Dissection, Pathologically positive

Recommended Articles

A comparison of endoscopic ultrasoundguided fine needle aspiration and fine needle biopsy for pancreatic masses, gastrointestinal subepithelial lesions, and lymph nodes

Background: Endoscopic ultrasound-guided tissue acquisition (EUS-TA) is a well-established diagnostic tool to obtain tissue from solid pancreatic masses, gastrointestinal subepithelial lesions, lymph nodes, liver as well as other neighboring organs. EUS-TA has proven to have a major clinical impact in diagnosis and staging, decreasing the need for invasive diagnostic procedures, such as thoracoscopy, mediastinoscopy, laparoscopy and open surgery.

BRCA1 and BRCA2 mutation variants in early breast cancer confer added prognostic information

Metastatic breast cancer to brain carries poor prognostic features with increased risks of occurrence in Tripple- negative and HER- positive breast tumors. In addition, tumors with mutated BRCA tumors, carry as well increased metastatic incidence. However, new clinical evidence suggest distinct clinical features between BRCA1 or BRCA2 mutated breast cancer and brain metastasis. Review of literature may help characterize the distinctive differences between BRCA1 or BRCA2 breast tumors and subsequent metastasis to brain.

Acute type A aortic dissection in a patient testing positive for Influenza A

Acute Type A aortic dissection (ATAAD) is a life-threatening condition, leading to rapid fatality if not promptly treated. The risk for Type A aortic dissection is increased in patients with preexisting thoracic aortic aneurysms, but specific triggering events leading to acute aortic dissection are incompletely understood. Our recent research suggests that influenza may be a risk factor for ATAAD by demonstrating a relationship between regional influenza activity and hospital admissions for ATAAD.

Probes for cancer metastasis imaging and therapeutic targeting

Metastasis of cancer is the process by which the primary tumor spreads from the original site to other parts of the body. Palliative care is the most common treatment option available for patients with metastatic cancer, but most patients eventually succumb to the disease due to the lack of therapeutics that can specifically target disseminated tumors [1].

HK2 fuels anoikis resistance to accelerate ICC metastasis

Intrahepatic cholangiocarcinoma (ICC), the second most frequent primary liver tumor, is a highly metastatic malignancy and often leads to disaster outcome in majority of patients, bringing significant challenges in the medical field [1].

Full Text
Cite
Download PDF
Author Information X